Format

Send to

Choose Destination
J Chemother. 2015 Feb;27(2):106-10. doi: 10.1179/1973947814Y.0000000228. Epub 2014 Dec 2.

Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?

Abstract

BACKGROUND:

The purpose of this study was to assess the efficacy and toxicity of radiotherapy (RT) with concurrent temozolomide (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG).

METHODS:

Patients younger than 18 years with newly diagnosed DIPG were enrolled. Children were treated with focal RT along with concurrent daily TMZ. Four weeks after completing the initial RT-TMZ schedule, adjuvant TMZ was given every 28 days up to 12 cycles or progression disease.

RESULTS:

Fifteen children with a median age of 9 years were enrolled. Fourteenth out of the 15 patients completed the chemoradiotherapy. The toxicity associated with TMZ was primarily haematopoietic. At a median follow-up of 15 months 13 children had died and 2 children were alive with progressive disease. No patient experienced complete response (CR). The median time to progression was 7.15 months.

CONCLUSION:

Chemoradiotherapy with TMZ followed by adjuvant TMZ did not improve the poor prognosis associated with DIPG in children.

KEYWORDS:

Children,; Diffuse intrinsic pontine glioma; Temozolomide,

PMID:
25466729
DOI:
10.1179/1973947814Y.0000000228
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center